Clinical Trial Update: Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer [Phase 2]

View source ↗

Summary

This phase II study tests adding the HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in newly diagnosed HPV-associated oropharyngeal squamous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• PRGN-2009
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING